Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

By R. Coleman. 2007

842 citations recorded by the source corpus.

Subfields: Reproductive Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/500690227ea4c90a7e1e5b364f9875ae9f247f27

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Reproductive Medicine

1. E. Lengyel
2. L. Kelland
3. C. Sessa
4. A. González-Martín

In Surgery

1. Guido Kroemer
2. E. Lengyel
3. L. Kelland

Citations in the corpus

• The biology of ovarian cancer: new opportunities for translation (2009, background): “Given the importance of disease on the peritoneal surface, intraperitoneal delivery of chemotherapy to achieve high local concentrations of a drug has substantially improved the survival of patients who have minimal gross disease remaining after surgery and who can tolerate the side effects of treat”
• The resurgence of platinum-based cancer chemotherapy (2007, methodology): “In support of this strategy, a recently completed phase III trial of over 400 patients (who had undergone surgery for ovarian cancer), compared the activity of intravenous paclitaxel on day 1 plus intravenous cisplatin on day 2 with that of intravenous paclitaxel followed by intraperitoneally admini”
• Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “One randomised clinical trial carried out by the GOG (GOG-172) demonstrated a benefit in PFS and OS for a regimen that included not only intraperitoneal cisplatin on day 2 and intravenous paclitaxel on day 1, but also intraperitoneal paclitaxel on day 8 [42].”
• Ovarian cancer development and metastasis. (2010, background): “administration.(6) The rationale for this treatment modality is based on the observation that ovarian carcinomas are generally restricted to the abdominal cavity and on pharmacodynamic studies that show that i.”
• Molecular mechanisms of cisplatin resistance (2012, background): “Moreover, in specific clinical settings, cisplatin represents by far the most prominent, if not the sole, therapeutic option (Armstrong et al., 2006).”